Company Performance Metrics
Fuad Rahman: CTOPast Role: Compliance Xpressware, CEO
Specialty drugs account for 2% of all drugs sold, but by 2018 will be 50% of the spend for drugs. Pinscriptive uses advanced big-data analytics and collaborative approaches to identify the right drugs, for the right patient at the right time, therefore reducing cost and improving outcomes. In essence, Pinscriptive will deliver evidence backed,
value-based decision support for at-risk providers and payers seeking to make the most appropriate specialty drug decision.
There is currently estimated to be up to $20billion in annual, solvable specialty Rx inefficiencies in the US alone. By identifying which drugs are most effective for which patients (precision analytics for precision medicine) Pinscriptive can significantly reduce costs for providers and payers. The business model also seeks to be collaborative with biopharma, as they too will face pay-for-performance pressures via risk-based contracting.
